Volume 8, Issue 1 (2023)
SJMR 2023, 8(1): 1-4 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Behjati F. The Application of Personalized Medicine in Female Cancers. SJMR 2023; 8 (1) : 1
URL: http://saremjrm.com/article-1-286-en.html
URL: http://saremjrm.com/article-1-286-en.html
Sarem Gynecology, Obstetrics and Infertility Research Center, Sarem Women’s Hospital, Iran University of Medical Science (IUMS), Tehran, Iran. &Sarem Cell Research Center (SCRC), Sarem Women’s Hospital, Tehran, Iran.
Abstract: (816 Views)
Personalized medicine, also known as “precision medicine,” is the science of individualizing cancer care by treating tumors based on their genetic makeup rather than their location of origin. Personalized medicine or precision medicine was first defined for management of cancer patients with the idea that information of patient’s genes, proteins, metabolites and environment can be applied for its individualized management and it encompasses prevention, screening, diagnosis, prognosis, treatment, follow up, detection of recurrence and categorization of patient to defined subgroups for more effective treatment. Current evidence suggests the relative success of this approach in cancer patients. The development and implementation of personalized medicine required a set of objectives and valid biomarkers through genomics, transcriptomics, and proteomics and metabolomics knowledge of huge sample cohorts regarding confounding factors, such as age, gender, habits, diet, and environment. Personalized medicine in reproductive medicine is still in its nonage since it is not yet a fully strengthened mature arena. Reproductive medicine is at the preliminary stage of discovering and validating genomic, protein and metabolite biomarkers. Perhaps what is currently being offered as personalized treatment of infertile patient is more based on “the best expert opinion of the attending clinician” than “the best evidence-based data available”.
Article number: 1
Article Type: Editorial |
Subject:
Women Diseases
Received: 2023/09/13 | Accepted: 2023/09/13 | Published: 2023/09/13
Received: 2023/09/13 | Accepted: 2023/09/13 | Published: 2023/09/13
References
1. 1. Barroilhet, L. and U. Matulonis, The NCI-MATCH trial and precision medicine in gynecologic cancers. Gynecologic Oncology, 2018. 148(3): 585-590. [DOI:10.1016/j.ygyno.2018.01.008]
2. Beim, P.Y., M. Elashoff, and T.T. Hu-Seliger, Personalized reproductive medicine on the brink: progress, opportunities and challenges ahead. Reproductive BioMedicine Online, 2013. 27(6): 611-623. [DOI:10.1016/j.rbmo.2013.09.010]
3. Sadeghi, M.R., How Can Personalized Medicine Improve Assisted Reproduction Technology Outcomes? J Reprod Infertil, 2017. 18(3): 265-266.
4. Zhang, P.Y. and Y. Yu, Precise Personalized Medicine in Gynecology Cancer and Infertility. Front Cell Dev Biol, 2019. 7: 382. [DOI:10.3389/fcell.2019.00382]
5. Verma, M., Personalized medicine and cancer. Journal of personalized medicine, 2012. 2(1): 1-14. [DOI:10.3390/jpm2010001]
6. de Souza, J.A. and O.I. Olopade. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. in Seminars in oncology. 2011. Elsevier. [DOI:10.1053/j.seminoncol.2011.01.002]
7. Arao, T., et al., What can and cannot be done using a microarray analysis? Treatment stratification and clinical applications in oncology. Biological and Pharmaceutical Bulletin, 2011. 34(12): 1789-1793. [DOI:10.1248/bpb.34.1789]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
